NOS2 and cancer: Thus, whereas the early stages of T cell activation remain unaffected in the presence of MDSCs, induction of DNA damage and p53 pathway activation via iNOS may account for the inhibition of T cell function and, in turn, decreased survival outcomes in cancer patients (Figure 5C).